​

Day One Biopharmaceuticals (DAWN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DAWN Stock Forecast

Day One Biopharmaceuticals (DAWN) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $38.80, with a high of $45.00 and a low of $24.00. This represents a 439.64% increase from the last price of $7.19.

$5 $13 $21 $29 $37 $45 High: $45 Avg: $38.8 Low: $24 Last Closed Price: $7.19

DAWN Stock Rating

Day One Biopharmaceuticals stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

DAWN Price Target Upside V Benchmarks

TypeNameUpside
StockDay One Biopharmaceuticals439.64%
SectorHealthcare Stocks 33.49%
IndustryBiotech Stocks 82.86%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$32.00
Last Closing Price$7.19$7.19$7.19
Upside/Downside--345.06%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25441--9
Mar, 25541--10
Feb, 25541--10
Jan, 25541--10
Dec, 24541--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 01, 2024Alec StranahanBank of America Securities$24.00$14.3167.71%233.80%
May 07, 2024Andrew MaldonadoH.C. Wainwright$40.00$16.60140.96%456.33%
Jan 08, 2023Joseph CatanzaroPiper Sandler$45.00$21.34110.87%525.87%
Dec 15, 2022H.C. Wainwright$35.00$21.6161.96%386.79%
Dec 14, 2022Needham$40.00$20.5394.84%456.33%
Dec 05, 2022Goldman Sachs$45.00$21.74106.99%525.87%
Jun 20, 2022Joseph CatanzaroPiper Sandler$40.00$15.79153.32%456.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024H.C. WainwrightBuyBuyhold
Oct 23, 2024Piper SandlerOverweightOverweighthold
Jul 08, 2024Piper SandlerOverweightOverweighthold
Jun 03, 2024Piper SandlerOverweightOverweighthold
May 07, 2024H.C. WainwrightBuyBuyhold
Apr 24, 2024Cowen & Co.BuyBuyhold
Jan 08, 2023Piper SandlerOverweightOverweighthold
Dec 14, 2022NeedhamBuyinitialise
Dec 05, 2022Goldman SachsBuyinitialise
Jun 20, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.37$-1.02----
Avg Forecast$-2.28$-0.74$-1.16$-0.23$0.55$1.49
High Forecast$-2.18$-0.61$-0.88$0.08$1.08$1.78
Low Forecast$-2.33$-1.35$-1.53$-0.57$0.07$1.08
Surprise %3.95%37.84%----

Revenue Forecast

$100M $210M $320M $430M $540M $650M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$131.16M----
Avg Forecast-$114.22M$166.94M$291.94M$412.01M$549.09M
High Forecast-$115.89M$190.72M$292.43M$412.21M$632.65M
Low Forecast-$111.44M$130.93M$291.46M$411.81M$434.30M
Surprise %-14.84%----

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-188.92M$-95.50M----
Avg Forecast$-179.58M$-84.29M$-117.79M$-37.06M$46.60M$118.81M
High Forecast$-173.64M$-48.66M$-70.13M$6.22M$86.12M$142.32M
Low Forecast$-185.53M$-107.76M$-122.04M$-45.44M$5.27M$86.52M
Surprise %5.20%13.29%----

DAWN Forecast FAQ

Is Day One Biopharmaceuticals stock a buy?

Day One Biopharmaceuticals stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Day One Biopharmaceuticals is a favorable investment for most analysts.

What is Day One Biopharmaceuticals's price target?

Day One Biopharmaceuticals's price target, set by 11 Wall Street analysts, averages $38.8 over the next 12 months. The price target range spans from $24 at the low end to $45 at the high end, suggesting a potential 439.64% change from the previous closing price of $7.19.

How does Day One Biopharmaceuticals stock forecast compare to its benchmarks?

Day One Biopharmaceuticals's stock forecast shows a 439.64% upside, outperforming the average forecast for the healthcare stocks sector (33.49%) and outperforming the biotech stocks industry (82.86%).

What is the breakdown of analyst ratings for Day One Biopharmaceuticals over the past three months?

  • April 2025: 44.44% Strong Buy, 44.44% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 50.00% Strong Buy, 40.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 50.00% Strong Buy, 40.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Day One Biopharmaceuticals’s EPS forecast?

Day One Biopharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.16, marking a 13.73% increase from the reported $-1.02 in 2024. Estimates for the following years are $-0.23 in 2026, $0.55 in 2027, and $1.49 in 2028.

What is Day One Biopharmaceuticals’s revenue forecast?

Day One Biopharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $166.94M, reflecting a 27.28% increase from the reported $131.16M in 2024. The forecast for 2026 is $291.94M, followed by $412.01M for 2027, and $549.09M for 2028.

What is Day One Biopharmaceuticals’s net income forecast?

Day One Biopharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-118M, representing an 23.35% increase from the reported $-95.496M in 2024. Projections indicate $-37.062M in 2026, $46.6M in 2027, and $118.81M in 2028.